BEDFORD, Ohio, July 12 /PRNewswire/ -- Bedford Laboratories, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
(Logo: http://photos.prnewswire.com/prnh/20070809/CLTH157LOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )
Dactinomycin, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic nonseminomatous testicular cancer. Dactinomycin is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. Dactinomycin, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.
Prescribing information is available upon request from the Bedford Laboratories’ professional services department at 800.521.5169, or from the company’s web site, www.bedfordlabs.com.
About Bedford Laboratories
Bedford Laboratories supplies the U.S. and International markets with multisource and specialty injectable products offering a broad range of multisource injectables across multiple therapeutic classes. Bedford Laboratories is one of the largest generic injectable pharmaceutical companies in the US. For more information on Bedford Laboratories, visit www.bedfordlabs.com.
About Ben Venue Laboratories, Inc.
Ben Venue Laboratories, Inc. (BVL) was founded in 1938 and is a leading contract manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. BVL has been under contract with the National Cancer Institute since 1967 to develop parenteral dosage forms for many anticancer agents. It has also manufactured various AIDS-specific drugs in conjunction with the NCI. BVL is located in Bedford, Ohio and employs more than 1,300 people. For more information on BVL and current career opportunities, visit www.benvenue.com.
BVL is a U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies. For more information, please visit http://us.boehringer-ingelheim.com.
Cosmegen® is a registered trademark of Lundbeck Inc.
SOURCE Bedford Laboratories
